Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA sanctions new version of Essure:

This article was originally published in Clinica

Executive Summary

A third-generation Essure permanent birth control system developed by Conceptus has gained approval from the US FDA. Conceptus says that the new version is superior to previous models due to its revamped delivery system, which has reduced the number of steps a physician must take when placing the device in the patient's fallopian tubes. In addition to being simpler to implant, the hysteroscopic visualisation of the implant and placement markers have also been improved, and a new DryFlow Introducer, which alleviates distension fluid loss, is being packaged with the product. The Essure procedure is the only FDA-approved female sterilisation procedure to prevent 100% of pregnancies in clinical trials, said the Mountain View, California firm.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049292

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel